A Closer Look: Is Double-Digit Growth Sustainable In Emerging Markets? (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
A new debate among investors concerns whether double-digit growth is possible across emerging markets or only in China. PharmAsia News takes a closer look.
You may also be interested in...
Seroquel Patent Expiration Leads To Sharp 2Q Revenue Decline For AstraZeneca
With U.S. revenues down 29% and the EU take off by 20%, perhaps AstraZeneca’s greatest concern is only 1% revenue growth in emerging markets, which the pharma has targeted as a key revenue-driver through its patent cliff.
Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In the last installment, we took a closer look at Sanofi SA and Merck & Co., in this edition we drill down on Novo Nordisk A/S, Roche Holdings AG and GlaxoSmithKline PLC ('Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1),' PharmAsia News, Aug. 8, 2011).
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
SHANGHAI - While Beijing is hosting China's National People's Congress this week to discuss and design its next Five-Year Plan, China's powerful National Development and Reform Commission announced another round of price cuts on antibiotics and cardiovascular drugs with an average price reduction of 21%, less than the rumored 30-40% cuts, but still a blow to Big Pharma